Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays

被引:130
作者
Chauhan, D
Auclair, D
Robinson, EK
Hideshima, T
Li, GL
Podar, K
Gupta, D
Richardson, P
Schlossman, RL
Krett, N
Chen, LB
Munshi, NC
Anderson, KC
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol Jerome Lipper Multiple, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA
[3] Northwestern Univ, Med Sch, Robert H Lurie Canc Ctr, Chicago, IL USA
关键词
multiple myeloma; dexamethasone; interleukin-6;
D O I
10.1038/sj.onc.1205205
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Our previous studies have characterized Dexamethasone (Dex)-induced apoptotic signaling pathways in multiple myeloma (MM) cells; however, related transcriptional events are not fully defined. In the present study, gene expression profiles of Dex-treated MM cells were determined using oligonucleotide arrays. Dex triggers early transient induction of many genes involved in cell defense/repair-machinery. This is followed by induction of genes known to mediate cell death and repression of growth/survival-related genes. The molecular and genetic alterations associated with Dex resistance in MM cells are also unknown. We compared the gene expression profiles of Dex-sensitive and Dex-resistant MM cells and identified a number of genes which may confer Dex-resistance. Finally, gene profiling of freshly isolated MM patient cells validates our in vitro MM cell line data, confirming an in vivo relevance of these studies. Collectively, these findings provide insights into the basic mechanisms of Dex activity against MM, as well as mechanisms of Dex-resistance in MM cells. These studies may therefore allow improved therapeutic uses of Dex, based upon targeting genes that regulate MM cell growth and survival.
引用
收藏
页码:1346 / 1358
页数:13
相关论文
共 67 条
[1]  
ALEXANIAN R, 1992, BLOOD, V80, P887
[2]  
Anderson KC, 1999, SEMIN HEMATOL, V36, P14
[3]  
ANDERSON KC, 1989, BLOOD, V73, P1915
[4]   Targeted therapy for multiple myeloma [J].
Anderson, KC .
SEMINARS IN HEMATOLOGY, 2001, 38 (03) :286-294
[5]   Bruton's tyrosine kinase links the B cell receptor to nuclear factor κB activation [J].
Bajpai, UD ;
Zhang, KM ;
Teutsch, M ;
Sen, R ;
Wortis, HH .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (10) :1735-1744
[6]   Control of apoptosis by Rel/NF-κB transcription factors [J].
Barkett, M ;
Gilmore, TD .
ONCOGENE, 1999, 18 (49) :6910-6924
[7]   INTERLEUKIN-6 FUNCTIONS AS AN INTRACELLULAR GROWTH-FACTOR IN HAIRY-CELL LEUKEMIA IN-VITRO [J].
BARUT, B ;
CHAUHAN, D ;
UCHIYAMA, H ;
ANDERSON, KC .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (05) :2346-2352
[8]   BIOLOGIC EFFECTS OF ANTI-INTERLEUKIN-6 MURINE MONOCLONAL-ANTIBODY IN ADVANCED MULTIPLE-MYELOMA [J].
BATAILLE, R ;
BARLOGIE, B ;
LU, ZY ;
ROSSI, JF ;
LAVABREBERTRAND, T ;
BECK, T ;
WIJDENES, J ;
BROCHIER, J ;
KLEIN, B .
BLOOD, 1995, 86 (02) :685-691
[9]   Nuclear factor-κB, cancer, and apoptosis [J].
Bours, V ;
Bentires-Alj, M ;
Hellin, AC ;
Viatour, P ;
Robe, P ;
Delhalle, S ;
Benoit, V ;
Merville, MP .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (08) :1085-1089
[10]  
CHAUDHRY A, 1994, ANTICANCER RES, V14, P2085